Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people starting semaglutide report that food cravings quiet down noticeably within the first few weeks — not because willpower improves, but because the medicine acts on appetite-regulating pathways in the brain. That shift is real, documented in clinical trials, and one of the reasons many people find it easier to eat less without feeling deprived. Wegovy is a prescription-only medicine, and a prescriber will assess whether it is clinically appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When someone asks about semaglutide cravings, they're usually trying to work out one of three things: whether the medicine will make dieting feel bearable, whether the cravings they still have are normal, or whether the effect will last. Those are three different questions, and they deserve three different answers.
The first is the hopeful one. Yes, for most people, Wegovy does reduce food cravings, and the mechanism matters. GLP-1 receptors aren't only in the stomach; they're in areas of the brain involved in reward and motivation. When semaglutide activates those receptors, the mental pull towards high-calorie foods tends to soften. This has been described in participant reports from the STEP 1 trial, published in the New England Journal of Medicine, where appetite and food-preference changes were noted alongside the headline weight-loss results. The NHS medicines page for semaglutide also describes reduced appetite as a central feature of how the treatment works.
So the starting point is encouraging. But it's not uniform, and it's not permanent on its own.
One thing our prescribers hear regularly: people are surprised when sweet cravings stick around longer than expected. This is actually well documented. Wegovy cravings patterns aren't monolithic. General hunger tends to drop first. The drive to eat for pleasure or habit (especially around sugar) can linger, partly because those behaviours are reinforced by years of routine, not just by hunger signals.
If you're noticing that sugar cravings on Wegovy feel stickier than other food urges, that's a common pattern, not a sign the medicine isn't working. The appetite change affects physiological hunger more reliably than it dismantles conditioned habits. Stress, poor sleep and skipping protein at meals can all keep cravings alive even when appetite is reduced. Addressing those factors alongside treatment tends to produce better results than relying on the medicine alone.
Timing matters too. For some people the effect deepens as the dose increases, which is a gradual process over several months. If you're wondering whether Wegovy reduces cravings more noticeably at higher doses, that question gets a detailed answer including what the clinical evidence actually shows. If cravings feel unchanged at 0.25mg or 0.5mg, that's not necessarily the ceiling; it may simply reflect where you are in the titration schedule.
Cravings returning is one of the more unsettling experiences people describe, especially if the first weeks felt transformative. There are a few reasons it happens. The most common is a missed or delayed injection. Semaglutide's half-life is long, which is why once-weekly dosing works, but a delay of several days can mean appetite and cravings creep back noticeably. If that happens consistently, it's worth mentioning to your prescriber; it may point to something about the timing of your injections, or whether your current dose is the right one.
A second pattern appears when weight loss stalls. The body adapts to lower calorie intake over time, and some of the behavioural flexibility the medicine provides can feel like it narrows. This is worth reading about in the context of what to do when semaglutide stops working, there are clinical options, and it's not inevitably a dead end.
It's also worth noting that cravings are partly a response to restriction. If someone is eating too little on Wegovy (skipping meals because appetite has disappeared entirely) a rebound effect is predictable. Adequate protein, regular meals and staying hydrated all make a practical difference. The NHS healthy weight guidance has practical diet pointers that sit alongside treatment rather than conflicting with it.
The reduction in cravings on Wegovy is best understood as a window, not a cure. It creates the conditions to build better habits (smaller portions feel more natural, the 11pm biscuit-tin pull weakens) but it doesn't rebuild the habits automatically. People who use that window deliberately, by restructuring meals, finding alternative evening routines, or working with a dietitian, tend to maintain more of their progress over time.
For those interested in the sweet craving side of Wegovy specifically, there's a more detailed look at what drives it and practical ways to manage it. And if you're weighing up whether Wegovy is the right treatment for you at all (including how it compares to other licensed options) our treatment overview covers the landscape plainly. Treatment cost is a real consideration too, and our Wegovy savings page explains the options available and what an honest price should include.
If your experience of cravings is shifting in a way that's making eating feel complicated or distressing, that's a signal to loop your prescriber in sooner rather than later. Our clinical team reviews every patient's progress, not just their initial assessment. You can find out more about how that works on the about us page.
Wegovy is a prescription-only medicine. Treatment requires a clinical assessment with a qualified prescriber, who decides whether it's appropriate for your individual situation. If you'd like to explore whether it's right for you, speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.